CD19 CAR-T cells + CD19 positive feeder T cells

CD19 CAR-T cells + CD19 positive feeder T cells is an investigational cell-based immunotherapy approach that combines chimeric antigen receptor (CAR) T cells targeting CD19 with the co-administration of autologous T cells engineered to express CD19 (CD19+ feeder T cells or FTCs). The CAR-T component consists of patient-derived T lymphocytes genetically modified using a lentiviral vector to express a synthetic receptor specific for the B cell marker CD19. This receptor typically includes an anti-CD19 single-chain variable fragment, a 4-1BB costimulatory domain, and a CD3 zeta activation domain. In some protocols, additional elements such as IL-6 shRNA are included to modulate cytokine release[2]. The addition of CD19+ FTCs serves as an artificial antigen source to stimulate and maintain CAR-T cell activity after infusion by providing persistent target engagement even when tumor burden is low or residual disease remains[2]. This strategy aims to enhance the expansion, persistence, and antitumor efficacy of CAR-T therapy in patients with relapsed/refractory B-cell malignancies such as acute lymphoblastic leukemia (B-ALL)[1][2][3]. Clinical studies have shown that this combination can restore lost responses in CAR-T treated patients and may extend therapeutic benefit[1][2].

Other names

anti-cd19 car t-cell consolidation therapy combined with cd19+ feeding t cellsanti-cd19 car t-cell therapy with cd19+ ftcs